Incyte (INCY) Scheduled to Post Quarterly Earnings on Tuesday

Incyte (NASDAQ:INCY) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, October 29th. Analysts expect the company to announce earnings of $1.10 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.78 by ($2.60). Incyte had a return on equity of 0.75% and a net margin of 2.52%. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the company posted $0.77 earnings per share. Incyte’s revenue for the quarter was up 9.3% on a year-over-year basis. On average, analysts expect Incyte to post $1 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Incyte Price Performance

Shares of INCY stock opened at $65.27 on Tuesday. Incyte has a 1 year low of $50.27 and a 1 year high of $70.36. The firm’s 50 day moving average is $64.87 and its 200-day moving average is $61.01. The firm has a market capitalization of $14.66 billion, a price-to-earnings ratio of 19.78, a PEG ratio of 5.30 and a beta of 0.73. The company has a current ratio of 1.92, a quick ratio of 1.84 and a debt-to-equity ratio of 0.01.

Wall Street Analysts Forecast Growth

INCY has been the topic of a number of research reports. William Blair reiterated an “outperform” rating on shares of Incyte in a research report on Monday, September 9th. JPMorgan Chase & Co. upped their target price on shares of Incyte from $59.00 to $61.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. JMP Securities reiterated a “market perform” rating on shares of Incyte in a research report on Tuesday, September 17th. Cantor Fitzgerald restated a “neutral” rating on shares of Incyte in a report on Monday, September 16th. Finally, Bank of America increased their price objective on shares of Incyte from $66.00 to $68.00 and gave the company a “neutral” rating in a report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $73.21.

Insider Buying and Selling at Incyte

In other news, EVP Vijay K. Iyengar sold 15,571 shares of the stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $70.00, for a total transaction of $1,089,970.00. Following the completion of the sale, the executive vice president now owns 36,701 shares of the company’s stock, valued at $2,569,070. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Jonathan Elliott Dickinson sold 8,450 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $62.36, for a total transaction of $526,942.00. Following the completion of the sale, the executive vice president now owns 36,390 shares of the company’s stock, valued at $2,269,280.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Vijay K. Iyengar sold 15,571 shares of the stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $70.00, for a total transaction of $1,089,970.00. Following the sale, the executive vice president now directly owns 36,701 shares of the company’s stock, valued at $2,569,070. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 24,593 shares of company stock valued at $1,652,914. Corporate insiders own 17.50% of the company’s stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.